Modality
mRNA
MOA
PD-1i
Target
GIP-R
Pathway
Epigenetic
Asthma
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
~Jul 2023
→ ~Oct 2024
NDA/BLA
Jan 2025
→ Jun 2028
NDA/BLACurrent
NCT04107614
224 pts·Asthma
2025-01→2028-06·Recruiting
224 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-242.2y awayPh3 Readout· Asthma
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2028-06-24 · 2.2y away
Asthma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04107614 | NDA/BLA | Asthma | Recruiting | 224 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R |